Hepion Pharmaceuticals Inc

NASDAQ:HEPA   3:53:46 PM EDT
1.06
0.00 (-0.47%)
Products

Hepion Pharmaceuticals Announces FDA Clearance Of Ind Application For CRV431 In The Treatment Of Liver Cancer

Published: 12/21/2021 13:15 GMT
Hepion Pharmaceuticals Inc (HEPA) - Hepion Pharmaceuticals Announces FDA Clearance of Ind Application for Crv431 in the Treatment of Liver Cancer.
Hepion Pharmaceuticals - Ind Clearance Allows Crv431 to Move Directly Into Phase 2 for Hepatocellular Carcinoma Treatment.
Hepion Pharmaceuticals - New Ind Expands Liver Disease Pipeline for Crv431.
Hepion Pharmaceuticals - New Ind Provides for Complementary Therapeutic Approach of Treating Nash and Liver Cancer With Single Once-a-day Oral Agent.
Hepion Pharmaceuticals - Larger Phase 2b Nash Study of Over 300 Subjects With Paired Liver Biopsies, Called 'ascend-nash', Expected to Initiate 2022.
Hepion Pharmaceuticals Inc - Ascend-nash Will Evaluate Crv431's Effects on Histologic Endpoints of Liver Steatosis and Fibrosis Over 12 Months Dosing.